Archive Newsletter

11. 01.20.26 -- STREAM Edition: Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos 1/20/2026

    01/20/26 Cell & Gene Newsletter

12. 01.20.26 -- Global Shifts And Strategic Resilience Will Shape CGT In 2026 1/20/2026
    01/20/26 Cell & Gene Newsletter
13. 01.19.26 -- Metrics, Not Audits, Should Lead Vendor Accountability 1/19/2026
    01/19/26 Cell & Gene Newsletter
14. 01.16.26 -- Balancing Innovation With Manufacturability When GMP-Grade Is Unavailable 1/16/2026
    01/16/26 Cell & Gene Newsletter
15. 01.15.26 -- Timing Tech Transfer With Complex Raw Materials 1/15/2026
    01/15/26 Cell & Gene Newsletter
16. 01.14.26 -- What 2025 FDA Warning Letters Tell Us About GMP Compliance 1/14/2026
    01/14/26 Cell & Gene Newsletter
17. 01.13.26 -- STREAM Edition: A 2025 Retrospective Of The Life Science Industry 1/13/2026
    01/13/26 Cell & Gene Newsletter
18. 01.13.26 -- Allogeneic Cell Therapy's Success Hinges On Perfecting The Platform 1/13/2026
    01/13/26 Cell & Gene Newsletter
19. 01.12.26 -- Driving Efficiency, Reducing Costs In Multi-Modal CGT Manufacturing 1/12/2026
    01/12/26 Cell & Gene Newsletter
20. 01.10.26 -- Cell & Gene Best Of December 1/10/2026
    01/10/26 Cell & Gene Newsletter